News Search Results
May 20, 2025, 09:17 ET InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
May 20, 2025, 09:17 ET InMode Announces Health Canada Certification of the IgniteRF Platform with the New QuantumRF Technology
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
May 19, 2025, 08:00 ET Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
May 18, 2025, 20:00 ET Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the release of its "2024 Environmental, Social and Governance (ESG) Report", highlighting the Company's
More news about: Innovent Biologics
May 16, 2025, 17:30 ET Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025.
More news about: Vanda Pharmaceuticals Inc.
May 16, 2025, 14:34 ET Graystone Eye awards Prime Vendor agreement to Medline
state-of-the-art technology and techniques – such as light-adjustable lens surgery - to its clinical and surgical services and by supporting several national ophthalmology clinical trials. The organization also recently launched a new Chronic Care Management program, designed to provide a holistic approach to Medicare-enrolled
More news about: Medline Industries, LP
May 16, 2025, 08:58 ET Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
May 14, 2025, 14:32 ET Piramal Pharma Limited Announces Results for Q4 and FY2025
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
May 14, 2025, 14:26 ET Piramal Pharma Limited Announces Results for Q4 and FY2025
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
May 14, 2025, 08:42 ET Eye Care Expansion Project Positions Nepal as Global Eye Care Innovator "God of Sight" Dr. Sanduk Ruit Kicks Off Multi-City U.S. Speaking Tour
l-eye-care-innovator-god-of-sight-dr-sanduk-ruit-kicks-off-multi-city-us-speaking-tour-302454742.html SOURCE Tilganga Institute of Ophthalmology
More news about: Tilganga Institute of Ophthalmology
May 14, 2025, 06:52 ET Mallinckrodt Presents Data on Real-World Outcomes with Acthar® Gel (repository corticotropin injection) at the International Congress on Systemic Lupus Erythematosus (LUPUS 2025)
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; and neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
May 13, 2025, 08:00 ET Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic
More news about: Mallinckrodt plc
May 13, 2025, 06:00 ET Strategic Partnership | Sanyou Bio and TransRecoBio Forge Strategic Alliance to Build a New Ecosystem for the Full Industry Chain
their core strengths in antibody drug discovery and innovative formulation manufacturing, with a focus on addressing major unmet clinical needs in ophthalmology, autoimmune diseases, metabolic disorders, anti-aging, and infectious diseases. Together, they will advance the development of cutting-edge formulations
More news about: Sanyou Bio
May 12, 2025, 10:16 ET Piramal Pharma Ltd. Continues to Invest In USA; $90M in Expansions of Two US Sites
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
May 12, 2025, 10:11 ET Piramal Pharma Ltd. Continues to Invest In USA; $90M in Expansions of Two US Sites
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
May 09, 2025, 11:00 ET Injectable Drug Delivery Market worth US$1,034.78 billion by 2030 with 8.4% CAGR | MarketsandMarkets™
Switzerland) is a leading biotech company specializing in in vitro diagnostics and pharmaceutical products for rare diseases, immunology, ophthalmology, and cancer. Its key injectable products include Hemlibra, Ocrevus, Phesgo, and Vabysmo. Roche collaborates with over 250 global partners and conducts
More news about: MarketsandMarkets
May 09, 2025, 07:30 ET Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
system, today announced new preclinical data on its melanocortin agonists PL9654 and PL9655 at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
More news about: Palatin Technologies, Inc.
May 08, 2025, 16:39 ET Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
targeting the melanocortin receptor system, today presented new data from the Phase 3 MELODY-1 study at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The updated responder analyses highlight PL9643's rapid onset of action, broad and statistically significant efficacy, and
More news about: Palatin Technologies, Inc.
May 08, 2025, 09:00 ET Luminopia Announces That Anthem Blue Cross and Blue Shield Has Approved Its Amblyopia Treatment for Coverage
said Dr. Derek Sprunger, Professor at Indiana University School of Medicine, Pediatric Ophthalmology & Strabismus. "We are witnessing a transformative moment in amblyopia care, with more children gaining access to a therapy that not only improves
More news about: Luminopia
May 08, 2025, 07:00 ET Avista Therapeutics Presents In Vivo Data for its AAV Capsid in Inherited Retinal Diseases at Association for Research in Vision and Ophthalmology 2025 Annual Meeting
intravitreal capsid for inherited retinal diseases, with lead indication in X-linked retinoschisis (XLRS), at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah.
More news about: Avista Therapeutics
May 07, 2025, 10:00 ET Unifeye Vision Announces Partnership with Brooks Eye Associates, Along with Strategic Growth Investment
surgery center operator with integrated practice management services to the ophthalmology market, announced today its partnership with Brooks Eye Associates, a Plano, Texas based ophthalmology practice and surgery center. Concurrently, UVP received a growth capital investment
More news about: Waud Capital Partners
May 07, 2025, 08:30 ET InMode to Present at Upcoming Investor Conferences and Events
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
May 07, 2025, 06:00 ET Notice of Nominees for Directors
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
May 06, 2025, 20:00 ET Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the completion of first patient dosing in the Phase 2 clinical study of efdamrofusp alfa (R&D code: IBI302),
More news about: Innovent Biologics
May 06, 2025, 18:30 ET Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
President and CEO of Formosa Pharmaceuticals. "Our experience with Apotex's Canadian team underscored their commitment to branded and differentiated ophthalmology products, giving us full confidence that APP13007 will reach ophthalmologists and patients in Mexico as swiftly
More news about: Formosa Pharmaceuticals Inc.,